Literature DB >> 6478445

A sensitive and specific radioimmunoassay for 1-beta-D-arabino-furanosylcytosine.

N Shimada, T Ueda, T Yokoshima, J Oh-Ishi, T Oh-oka.   

Abstract

In order to determine the blood level of 1-beta-D-arabinofuranosylcytosine (Ara-C), an antileukemic agent, a sensitive and specific radioimmunoassay (RIA) system using anti-Ara-C serum, [5-3H] Ara-C and a dextran-coated charcoal method has been developed. The anti-Ara-C serum obtained from a guinea pig was hardly cross-reactive with 1-beta-D-arabinofuranosyluracil (Ara-U), tetrahydrouridine (THU) and other Ara-C analogues. The RIA system for Ara-C could detect concentrations as low as 60 pg/ml in plasma. Average of the intra- and inter-assay variancies at 5, 10, 20 ng/ml were 4.3% and 5.6%, respectively. Ara-C in blood samples obtained from human patients who orally received N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine (PL-AC) was determined by the present RIA system.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6478445     DOI： 10.1016/0304-3835(84)90133-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  7 in total

1.  Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis.

Authors:  Makoto Takeuchi; Takahiro Yamauchi; Isao Yoshida; Ryo Soda; Takanori Ueda; Kiyoshi Takahashi
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

2.  Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  R Ohno; K Kimura; K Ota; Y Miura; A Hoshino; K Hattori; M Hirano; M Ito; T Maekawa; T Nakamura
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

3.  Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers.

Authors:  R R Bowsher; J A Compton; J A Kirkwood; G D Place; C D Jones; T E Mabry; D L Hyslop; B L Hatcher; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

4.  Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.

Authors:  T Ueda; T Nakamura; D Kagawa; M Uchida; N Domae; M Sugiyama; Y Ueda; M Sasada; H Uchino
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.

Authors:  T Yamauchi; Y Kawai; N Goto; S Kishi; S Imamura; A Yoshida; Y Urasaki; T Fukushima; H Iwasaki; H Tsutani; M Masada; T Ueda
Journal:  Jpn J Cancer Res       Date:  2001-09

6.  Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.

Authors:  T Yamauchi; Y Kawai; S Kishi; N Goto; Y Urasaki; S Imamura; T Fukushima; A Yoshida; H Iwasaki; H Tsutani; M Masada; T Ueda
Journal:  Jpn J Cancer Res       Date:  2001-05

7.  Validation of a Novel Potentiometric Method Based on a Polymeric PVC Membrane Sensor Integrated with Tailored Receptors for the Antileukemia Drug Cytarabine.

Authors:  Ayman H Kamel; Abd El-Galil E Amr; Nashwa H Ashmawy; Hoda R Galal; Abdulrahman A Almehizia; Teraze A Youssef; Mohamed A Al-Omar; Ahmed Y A Sayed
Journal:  Polymers (Basel)       Date:  2020-06-14       Impact factor: 4.329
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.